Trial Profile
A Study to Evaluate the Efficacy of Erlotinib in Non Small Cell Lung Cancer (NSCLC) Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumours
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Dec 2015 New trial record